Corvus Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
863 Mitten Rd Ste 102, Burlingame, Calif...Phone Number
(650) 900-4520Website
www.corvuspharma.comRevenue
-Stock Symbol
CRVSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus focuses on bringing medicines to patients with the most difficult-to-treat cancers. Corvus is headquartered in Burlingame, California.Explore more
Corvus Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Corvus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Corvus Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Corvus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Corvus Pharmaceuticals has new funding data
Click to see if Corvus Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Corvus Pharmaceuticals
Check out if Corvus Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Corvus Pharmaceuticals launches new products
Corvus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Corvus Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Corvus Pharmaceuticals
Compare insights from companies similar to Corvus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Corvus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Corvus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Corvus Pharmaceuticals.
Corvus Pharmaceuticals financials insights
Gather financial insights about Corvus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$33.5M
2015
Series B
$75M
2016
Stock Offering
$71M
2018
Stock Offering
$64.8M
Corvus Pharmaceuticals Tech Stack
A closer look at the technologies used by Corvus Pharmaceuticals
See more technologies
Most Recent Scoops
Hiring Plans
Corvus Pharmaceuticals has more open roles in Human Resources than it has had at any time in the past 12 months. Areas of expertise include: Compensation Management, Recruitment Planning, Employee Relations, Talent Management, Human Resources Concepts, HR Regulations, and Onboarding Strategies.
Hiring Plans
Open Position
Person-Based
Earnings, Financial Reporting, Finance
Project
Corvus Pharmaceuticals has highlighted that soquelitinib's mechanism of action via ITK inhibition, which reduces both Th2 and Th17 cell function, may offer an advantage in Asian atopic dermatitis patients, who are reported to have a greater Th17 disease component and lower response rates to IL-4 and IL-13-targeted therapies such as dupilumab.
Person-Based
Earnings, Clinical Operations, Finance
Corvus Pharmaceuticals News & Media
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthmaCorvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
On August 6, Corvus Pharmaceuticals (NASDAQ:CRVS) held its second-quarter 2026 earnings call, and the story was almost entirely about one molecule. Soquelitinib, the company’s oral ITK inhibitor, is now being tested across five different diseases at once, from a rare blood cancer to asthma. That kind of breadth from a single-asset biotech is either a […]Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on trackCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Corvus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus focuses on bringing medicines to patients with the most difficult-to-treat cancers. Corvus is headquartered in Burlingame, California.... Read More
